Molecular tests such as phosphoinositide 3-kinase mutations, breast cancer susceptibility gene 1 or 2 mutations (BRCA1 OR BRCA2) and PD-L1 expression were not done and the relevant targeted therapy was not given. This evidence concerns the gene BRCA2 and breast cancer.